How Third-Party Remote Monitoring May Redefine Outcomes for Cardiac Device Patients

As healthcare systems continue to shift toward value-based care and proactive disease management, remote monitoring has become a cornerstone of chronic care delivery —especially in cardiology. Among patients with implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds), real-time monitoring offers the promise of earlier intervention, reduced hospitalizations and better quality of life.

June 6, 2025 – A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events and inpatient admissions. This is the first retrospective trial to evaluate the clinical impact of GLP-1 RAs for patients with moderate PAD. Findings were presented during the Society for Vascular  Surgery’s Vascular Annual Meeting, in New Orleans, Louisiana. 

June 5, 2025 – Penumbra, Inc. has announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby XL System, the longest, largest and softest coil on the market[i]. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolization[ii].

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons, finds that Medicare patients with atrial fibrillation (AF) who undergo surgical ablation during isolated coronary artery bypass grafting (CABG) live longer than those who do not, offering compelling support for clinical guidelines that recommend this procedure but are too often not followed in practice.

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia  (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Congress scientific sessions in Vienna, Austria.

KERENDIA is currently approved to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), non-fatal myocardial infarction (MI), sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).1

May 30, 2025 — BiVACOR, a clinical-stage medical device company developing the world’s first titanium Total Artificial Heart (TAH), announced that its device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

May 28, 2025 — Siemens Healthineers has introduced the first mobile stroke unit (MSU) featuring the Somatom On.site head computed tomography (CT) scanner in the United States.

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease. This therapy is available for patients whose mitral valves are not functioning properly due to severe mitral annular calcification (MAC), a buildup of calcium within the ring-like structure (known as an annulus) that supports the mitral valve.

May 27, 2025 — CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of DisaggproT (zalunfiban), an investigational heart-attack drug designed for rapid use at first point of medical contact – including before patients reach the hospital.

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities with long-term economic or social challenges still face barriers to cutting-edge therapies such as gene editing, according to a 2020 American Heart Association presidential advisory.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now